KRTL Holding Group Inc. announced today that its majority-owned subsidiary, KRTL Biotech, is showcasing its expanded range of anti-infective and antibiotic products. This initiative aims to improve access to essential medicines in underserved healthcare markets.
The current product line features essential formulations, including broad-spectrum antibiotics and antiparasitics. KRTL Biotech plans to leverage SIGMA Corp.’s GMP-certified facilities, which allow for the production of a wider array of anti-infective therapies, including various antibiotics and injectable medications.
Aligned with the World Health Organization’s Model List of Essential Medicines, KRTL Biotech’s offerings are designed to address urgent public health needs worldwide. The global anti-infectives market is projected to exceed $150 billion annually, driven by demand from healthcare institutions and emerging markets.
With operations in South America and efficient logistics from its facility in Bolivia, KRTL Biotech aims to compete on both cost and quality. Their scalable, compliant manufacturing processes position them to effectively supply healthcare systems and procurement agencies with reliable anti-infectives.
KRTL Biotech is currently exploring regulatory pathways to introduce select formulations into U.S. and international markets, further enhancing its global impact.
For more information, visit the primary source at GlobeNewswire.
